author-photo

Jean-Louis Legoux

University of Lorraine

96

Papers

1909

Citations

Citation Trend

Filter By

Papers (66) Sort By

Journal Conference Others

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk stage II and III colon cancers? Three years’ follow‐up results of the PRODIGE 22 phase II randomized multicenter trial

2021 Colorectal Disease
Show All
- Source
- Cite
- Save
Citations (2)
Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study.

2021 Clinics and Research in Hepatology and Gastroenterology
Show All
- Source
- Cite
- Save
Citations (0)
Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Panel gene profiling of small bowel adenocarcinoma, results from the NADEGE prospective cohort.

2020 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years’ follow-up results of the Prodige 22 phase II randomized multicenter trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Small bowel adenocarcinoma: results from a nationwide prospective ARCAD‐NADEGE cohort study of 347 patients

2020 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (16)
1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)